BiotechTube
Mycovia Pharmaceuticals

Mycovia Pharmaceuticals

Durham, United States· Est.
mycovia.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $85M

Overview

Mycovia Pharmaceuticals is a private, commercial-stage biotech founded in 2018, headquartered in the Research Triangle Park. The company has successfully brought its first product, VIVJOA, to market for recurrent vulvovaginal candidiasis (RVVC), representing a significant advancement in a chronic, underserved women's health condition. With a leadership team rich in pharmaceutical development and antifungal expertise, Mycovia is positioned to capitalize on this approved therapy while potentially expanding its pipeline into other antifungal indications. The company operates with a therapeutics business model and is now in a revenue-generating stage.

Women's HealthInfectious Disease

Technology Platform

Development of novel small-molecule antifungal agents with selective targeting of fungal CYP51 to minimize human off-target effects.

Funding History

2
Total raised:$85M
Series B$60M
Series A$25M

Opportunities

VIVJOA addresses a massive unmet need as the first and only FDA-approved therapy for RVVC, a chronic condition affecting millions of women.
The company has a significant first-mover advantage in a specialized women's health market with high demand for effective solutions.
There is potential for lifecycle management, including geographic expansion and exploration of oteseconazole in other fungal indications.

Risk Factors

The company faces high commercial execution risk as a newly launched entity with a single product.
Its financial and operational success is entirely dependent on the market uptake of VIVJOA.
The concentrated pipeline also exposes the company to significant competitive and clinical risks if new entrants emerge or if any post-marketing safety issues arise.

Competitive Landscape

In RVVC, VIVJOA's primary competition is the off-label, episodic use of generic fluconazole, which is inexpensive but not approved for chronic suppression. VIVJOA's differentiated profile as a chronic therapy with a specific mechanism offers a competitive edge. The landscape could evolve if other companies develop novel antifungal agents or seek label expansions for existing drugs into the RVVC space.

More companies in Small Molecule Drugs →More companies in United States →